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Abstract
It is believed that respiratory mucosal immunization triggers more effective immune protection
than parenteral immunization against respiratory infection caused by viruses and intracellular
bacteria. Such understanding has led to the successful implementation of intranasal immunization
in humans with a live cold-adapted flu virus vaccine. Furthermore there has been an interest in
developing effective mucosal-deliverable genetic vaccines against other infectious diseases.
However, there is a concern that intranasally delivered recombinant viral-based vaccines may
disseminate to the CNS via the olfactory tissue. Initial experimental evidence suggests that
intranasally delivered recombinant adenoviral gene transfer vector may transport to the olfactory
bulb. However, there is a lack of quantitative studies to compare the relative amounts of transgene
products in the respiratory tract, lung, olfactory bulb and brain after intranasal mucosal delivery of
viral gene transfer vector. To address this issue, we have used fluorescence macroscopic imaging,
luciferase quantification and PCR approaches to compare the relative distribution of transgene
products or adenoviral gene sequences in the respiratory tract, lung, draining lymph nodes,
olfactory bulb, brain and spleen. Intranasal mucosal delivery of replication-defective recombinant
adenoviral vector results in gene transfer predominantly in the respiratory system including the
lung while it does lead to a moderate level of gene transfer in the olfactory bulb. However,
intranasal inoculation of adenoviral vector leads to little or no viral dissemination to the major
region of the CNS, the brain. These experimental findings support the efficaciousness of intranasal
adenoviral-mediated gene transfer for the purpose of mucosal immunization and suggest that it may
not be of significant safety concern.
Background
It is increasingly believed that respiratory mucosal immu-
nization will trigger more effective immune activation
and protection against respiratory infection caused by
viruses and intracellular bacteria. Indeed, such under-
standing has led to the successful development and licen-
sure of a live cold-adapted flu virus vaccine that is given
intranasally to healthy humans of 5–49 years of age [1].
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This flu vaccine was shown to be well-tolerated, safe and
efficacious [1,2]. Recently, a replication-deficient recom-
binant adenovirus-based flu vaccine expressing hemaglu-
tinin was evaluated in healthy human subjects following
intranasal administration and was found to be safe and
more effective than cutaneous patch immunization [3].
Mounting experimental evidence from us and others sug-
gests that intranasal immunization with recombinant
viral-vectored or adjuvanted protein vaccines is more
effective than parenteral immunization against pulmo-
nary tuberculosis [4-8]. Based on all of these findings,
there has been a strong interest in promoting the develop-
ment and ultimate application of additional vaccine can-
didates, particularly viral-vectored vaccines, for human
intranasal immunization against respiratory pathogens.
Since the nose has been widely explored as a site of deliv-
ery of drugs to the cerebro-spinal fluid and the CNS [9],
there is a concern that intranasally delivered recombinant
viral-based vaccines may disseminate to the CNS via the
olfactory tissue. In this regard, several recent studies using
recombinant adenoviral gene transfer vectors expressing
LacZ or placental alkaline phosphatase (P1AP) have local-
ized the transgene products to the olfactory tissue follow-
ing intranasal inoculation in rodents [10-12]. However,
there has been a lack of quantitative studies to compare
the relative amounts of transgene products in the respira-
tory tract, lung, olfactory bulb and brain after intranasal
mucosal delivery of a viral gene transfer vector. In our cur-
rent study, we have used fluorescence macroscopic imag-
ing, luciferase quantification and PCR approaches to
compare the relative distribution of transgene products or
adenoviral gene sequences in the respiratory tract, lung,
cervical draining lymph nodes, olfactory bulb, brain and
spleen. The knowledge from our study helps address the
important safety issue associated with genetic intranasal
mucosal vaccination.
Methods
Experimental animals
Female BALB/c mice 6 to 10 weeks of age purchased from
Harlan Laboratory (Indianapolis, IN, USA) were housed
under SPF conditions. All experiments were conducted
following the guidelines of the Animal Research Ethics
Board of McMaster University.
Intranasal inoculation of adenoviral gene transfer vectors
For whole organ GFP imaging analysis, a replication-
defective recombinant human type 5 adenoviral vector
expressing green fluorescent protein (AdGFP) was used at
the dose of 5 × 107 pfu per mouse. For luciferase assay, a
replication-defective recombinant human type 5 adenovi-
ral vector expressing luciferase (AdLuc) was used also at
the dose of 5 × 107 pfu per mouse. Transgene expression
by both vectors is driven off of a murine CMV promoter
which represents an optimal promoter for adenoviral vec-
tors allowing high levels of transgene expression in vari-
ous tissues [13,14]. An empty replication-defective
recombinant human type 5 adenoviral vector (Addl) was
used as a control at the same dose. All adenoviral vectors
were amplified in 293 cells and purified according to the
protocols that we previously described [15]. The level of
replication competent adenovirus (RCA) contamination
in these preparations is below 0.000001% as determined
by infecting A549 cells for at least 17 days with serially
diluted viruses. A549 cells are recommended as a com-
monly used cell line in the method of testing for RCA
although an improved two-cell line bioassay has been
developed for this purpose in cases where the transgene
product may potentially interfere with the A549 system
[16]. Before use, the adenoviral based vectors were diluted
in PBS to a total volume of 25 μl/mouse. For intranasal
inoculation, mice were first lightly anesthetized with iso-
fluorane and the adenoviral preparation was delivered to
a nostril drop-wise with a pipette as previously described
[4,5]. For the assessment of whole organ GFP fluorescence
imaging, one mouse was used for each time point per each
vector treatment (including the control), and three inde-
pendent experiments were performed to verify the results.
For the luciferase assay, three mice were set up per time
point/gene transfer vector treatment and one mouse was
used as control for each time point/control vector. In a
separate experiment, mice were infected with AdLuc and
various organs were then harvested, fixed in 10% forma-
lin, processed, and stained with hematoxylin and eosin
(H&E) for histologic assessment. Two mice were used per
time point and the mice were sacrificed at days 1, 3, 7 and
12 post-intranasal inoculation.
Whole organ fluorescence imaging
At various times post-AdGFP i.n delivery, mice were sacri-
ficed and the fresh tissues including trachea, lung, cervical
lymph nodes, spleen, olfactory lobes and brain were har-
vested and immediately subjected to GFP fluorescence
imaging. Imaging was carried out using the LEICA MZ16F
fluorescence stereomicroscope with GFP2 filter and the
processing software OpenLab 4.0.4 at proper zoom
ranges. The exposure time for image taking was between 1
to 4 minutes varied with the intensity of fluorescence.
Tissue preparation and luciferase assay
Tissues were wrapped in aluminum foil, snap-frozen in
liquid nitrogen and stored at -70°C until homogeniza-
tion. The frozen samples were thawed in 1× CCLR (Cell
culture lysis reagent, Part No: E153A, Promega) in 15 ml
polypropylene tubes (1 ml CCLR for brain, lungs and
spleen and 400 μl for olfactory lobes, lymph nodes and
trachea). Tissues were homogenized for 30 seconds with
tubes in ice, and then spun for 10 min at 3,000 rpm at
4°C. Immediately, 20 μl of supernatants were transferredGenetic Vaccines and Therapy 2008, 6:5 http://www.gvt-journal.com/content/6/1/5
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into a luminometer plate (Microtiter Plates, Part No 7571,
Thermo) in duplicate for each sample. Luciferase and sub-
strate reaction was carried out by using the Promega Luci-
ferase assay system (Cat No E1500, Promega), which
allows for less than 10-20 moles of luciferase to be meas-
ured. Luciferase activity was quantified and expressed as
relative luciferase units/per gram total tissue proteins on
Microplate Luminometer TROPIX.
PCR assay for detection of adenoviral gene sequences in 
the tissue
Four mice were i.n infected with AdLuc at the dose of 5 ×
107 pfu per mouse and sacrificed three days post-infec-
tion. To extract tissue genomic DNA, whole organs were
wrapped in aluminum foil, snap-frozen in liquid nitrogen
and stored at -70°C. The organs were then thawed and
homogenized for 30 seconds in TRIZOL® Reagent (Cat No
15596-018, Invitrogen). Total tissue DNA was obtained
according to the manufacturer's DNA Isolation Protocol.
Polymerase Chain Reaction (PCR) amplification of a sec-
tion of the adenoviral genome (primer annealing to the
Ad5 genome in the vector: 5'-CGG AAC ACA TGT AAG
CGA CG-3'; primer annealing to the mCMV promoter in
the vector: 5'-GCT GGT CGC GCC TCT TAT AC-3';
expected size 720 bp) and the Glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) housekeeping gene as a
control (forward primer: 5'-AAT GCA TCC TGC ACC ACC
AAC TGC-3'; reverse primer: 5'-GGA GGC CAT GTA GGC
CAT GAG GTC-3'; expected size 550 bp) was performed.
For each tissue, 4 μl of DNA at ~0.025 μg/μl was subjected
to 35 cycles of PCR. The PCR reactions were electro-
phoresed through a 1% agarose gel, stained with ethidium
bromide, and visualized under UV light. All target and
control PCRs were done in triplicate.
Results and Discussion
Intranasal instillation of replication-defective recombinant 
adenoviral vector
Intranasal (i.n) instillation has been widely used to derive
transgene expression within the respiratory tract, but the
delivery methods may vary depending on the purpose of
gene transfer. In our current study, in order to adequately
address the organ distribution issue related to intranasal
mucosal vaccination, we have used the same method of
i.n delivery and the dose of adenoviral vector that we have
employed for the purpose of intranasal adenoviral-medi-
ated vaccination against pulmonary tuberculosis [4,5].
More specifically as we described above, a relatively small
volume of viral preparation was delivered i.n to mice that
were lightly anesthetized and were in upright position. We
have previously found that using a replication-defective
adenoviral-vectored TB vaccine expressing M.tb Ag85A
antigen represents an effective way of intranasal mucosal
immunization against subsequent pulmonary M.tb chal-
lenge [4-6].
Distribution of transgene product by organ fluorescence 
macroscopic imaging after intranasal adenoviral vector 
delivery
To compare the relative distribution of transgene protein
at various tissue sites following intranasal delivery of
recombinant adenoviral gene transfer vector, we first used
a recombinant replication-deficient adenoviral vector
expressing green fluorescent protein (AdGFP). Use of this
vector allowed us to conveniently assess the overall whole
organ distribution of transgene protein by fluorescence
macroscopy in freshly harvested tissues, without further
tissue processing and manipulation. At days 1, 3, 7 and 12
following i.n delivery of a dose of 5 × 107 pfu AdGFP or a
control Ad vector (Addl70-3), mice were sacrificed and
their trachea, lung, olfactory bulb, brain, cervical draining
lymph nodes and spleen were harvested and subjected to
fluorescence macroscopy. As expected, no intense green
fluorescence was detected at any time on organs of mice
receiving control Ad vector (data not shown). However,
following i.n delivery of AdGFP, there was patchy GFP
expression on the interior surface of trachea at days 1 and
3 and subsequently declined (Fig. 1). By day 12, no GFP
was seen in trachea. In comparison, by day 1 while GFP
fluorescence was seen in the lung it intensified between
days 3 and 7 (Fig. 1). By day 12 although the intensity
decreased, GFP could still be seen in the lung. These over-
all kinetics of transgene expression in the lung are in
agreement with our previous findings [17,18].
As there is evidence that in addition to infecting the epi-
thelium of the respiratory system, intranasally delivered
recombinant adenoviral vector may also infect the olfac-
tory epithelium and neurons and subsequently the olfac-
tory bulb via retrograde transport [10,11], we examined
whether our i.n delivery method would also lead to viral
gene transfer to the olfactory bulb of the CNS. Different
from the respiratory tract, at day 1 we did not observe sig-
nificant GFP in the olfactory region (Fig. 2). However, sig-
nificant GFP was observed between days 3 and 12 (Fig. 2).
These results suggest that in accord with studies by others
[10], the intranasally delivered adenoviral gene transfer
vector did get subsequently transported over to the olfac-
tory bulb. The initial delay in transgene expression in the
olfactory region, compared to relatively early expression
in the trachea and lung (Fig. 1) may be due to the fact that
the virus has to overcome the nasal/olfactory mucosal bar-
rier and be transported via the olfactory nerve before it can
reach the olfactory bulb.
As recombinant adenoviral gene transfer could reach the
olfactory bulb as shown now by us and previously by oth-
ers [10-12], it raises the question whether it may also
reach the main part of the CNS, the brain. Upon examina-
tion of the brain excluding the olfactory lobes, however,
we did not find any significant GFP (Fig. 2). This suggestsGenetic Vaccines and Therapy 2008, 6:5 http://www.gvt-journal.com/content/6/1/5
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that although i.n delivery leads to significant dissemina-
tion of adenoviral vector to the olfactory region, adenovi-
ral vector unlikely affects other major parts of the CNS.
Likewise, Lemiale and colleagues did not find any trans-
gene product activities in the brain after i.n delivery of an
adenoviral vector expressing placental alkaline phos-
phatase [10].
We found relatively faint GFP fluorescent patches/spots in
the cervical draining lymph nodes, whereas we found no
GFP at all in the spleen (data not shown). It was expected
that small amounts of virus or virus-infected antigen pre-
senting cells may migrate into the cervical lymph nodes
which drain the nasal passage.
Quantification of transgene product in various organs by 
luciferase assay after intranasal adenoviral vector delivery
In spite of the advantage of the fluorescence imaging tech-
nique, it cannot allow a quantitative assessment for com-
parison with regard to the extent of viral dissemination
following i.n mucosal gene transfer. Furthermore, organ
surface GFP imaging may miss viral infection that may
have occurred in deep tissue. To this end, we used a
recombinant replication-defective adenoviral gene trans-
fer vector expressing luciferase (AdLuc) for i.n delivery
and at various times after i.n, whole organs were homog-
enized and luciferase activities were quantified using the
luciferase assay in the trachea, lung, olfactory bulb, brain,
cervical draining lymph nodes and spleen. Consistent
with GFP imaging, the trachea had moderate levels of luci-
ferase activities following i.n gene transfer which could be
detected from day 1 and declined to the baseline by day
12 (Fig. 3A). In comparison, of all of the organs exam-
ined, the lung produced the highest levels of luciferase
activities which rose at day 1, peaked at days 3 and 7 and
markedly decreased at day 12 (Fig. 3B). The levels of luci-
ferase activities in the olfactory bulb, although also much
lower than those in the lung, were in general higher than
those in the trachea (Fig. 3C & Table 1), in basic agree-
ment with fluorescence intensities detected in this tissue
(Fig. 2). Upon comparison, the overall luciferase activities
in the lung at peak times were 15–20 times that in the
olfactory bulb (Table 1). However, compared to the lower
trend of luciferase activities in other tissues by day 12, the
Fluorescence images of the trachea and lung following i.n delivery of AdGFP Figure 1
Fluorescence images of the trachea and lung following i.n delivery of AdGFP. After intranasal delivery of AdGFP, mice were 
sacrificed at days 1, 3, 7 and 12 (one mouse/time point) and freshly harvested organs were subject to fluoroscopic imaging. 
Magnifications (zoomrange): trachea ×20; lung ×7. The images are representative of three independent experiments.
Day 1  Day 3  Day 7  Day 12
trachea
lungGenetic Vaccines and Therapy 2008, 6:5 http://www.gvt-journal.com/content/6/1/5
Page 5 of 9
(page number not for citation purposes)
level in the olfactory bulb at this time was still sustained.
This could be due to a relative lack of inflammatory infil-
trates in this tissue (see Table 2).
Consistent with the lack of GFP by fluorescence imaging,
luciferase activities in the main part of the brain were neg-
ligible (Fig. 3D & Table 1), close to those in the negative
control brains (Fig. 3F & Table 1). These thus further sug-
gest the lack of any significant dissemination of intrana-
sally delivered replication-defective recombinant
adenoviral gene transfer vector to the large part of the
CNS. This differs sharply from significant transgene
expression detected in the olfactory region of the CNS
(Fig. 2, Fig. 3C and Table 1), suggesting that such differen-
tial distribution of transgene product in the two different
areas of the CNS is due to retrograde viral trafficking from
the nasal mucosa, but not due to differential viral infectiv-
ity or promoter activities. By using a quantitative measure
of transgene expression, our current study lends support
to the conclusion drawn from other independent studies
[10-12]. While the overall luciferase activities in the cervi-
cal lymph nodes were small, there was an unquestionable
Fluorescence images of the olfactory bulb and brain following i.n delivery of AdGFP Figure 2
Fluorescence images of the olfactory bulb and brain following i.n delivery of AdGFP. After intranasal delivery of AdGFP, mice 
were sacrificed at days 1, 3, 7 and 12 (one mouse/time point) and freshly harvested organs were subject to fluoroscopic imag-
ing. Magnifications (zoom range): olfactory bulb ×25; brain ×7. The images are representative of three independent experi-
ments.
Day 1  Day 3  Day 7  Day 12
Olfactory
bulb
Brain
Table 1: Average values of luciferase activity in various tissues
Trachea Lung Olfactory bulb Brain LN Spleen
D1 3595 33728 14236 61 1 -23
D3 7718 136723 6794 29 4268 -4
D7 6046 186197 11677 49 83 4
D12 26 47428 16226 5 33 -3
The average luciferase units/gram tissue were determined from three mice/time point. The data are expressed as mean value of RLU/gram tissue 
proteins except the trachea (RLU/trachea) obtained by subtracting the background values of each set of control mouse tissues from the original 
measurement.Genetic Vaccines and Therapy 2008, 6:5 http://www.gvt-journal.com/content/6/1/5
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Quantification of luciferase activities in various organs following i.n delivery of AdLuc Figure 3
Quantification of luciferase activities in various organs following i.n delivery of AdLuc. After intranasal delivery of AdLuc, mice 
were sacrificed at days 1, 3, 7 and 12. The trachea (A), lung (B), olfactory bulb (C), brain (D), cervical lymph nodes (E) and 
spleen (F) were harvested and processed for the luciferase assay. Results are expressed as mean ± SEM from three mice/time 
point for AdLuc treatment. One mouse/time point was set up for naïve control measurement. The significance of differences in 
luciferase activities in the lung is as follows: it is significantly different between days 3/7 and day 1 or day 12 (p ≤ 0.01), but the 
difference between day 3 and day 7 is not significant (p = 0.1). There is no statistically significant difference between all time 
points in Fig. 3C.
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Table 2: Relative level of tissue inflammation after intranasal Ad inoculation
Lung Liver Heart Kidney Brain
D 1 -----
D 3 + ± ---
D7 +++ + - - -
D 1 2 + + + ----
The grading of extent of tissue inflammation: "-" no inflammatory infiltrate seen; "+" or "± ", very mild inflammatory infiltration; "+++" significant 
inflammatory infiltration.Genetic Vaccines and Therapy 2008, 6:5 http://www.gvt-journal.com/content/6/1/5
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Histologic assessment of tissue inflammation after intranasal Ad inoculation Figure 4
Histologic assessment of tissue inflammation after intranasal Ad inoculation. After intranasal delivery of AdLuc, mice were sac-
rificed at days 1, 3, 7 and 12 and the organs were fixed, processed, and stained with H&E. Open arrow: inflammatory infiltrates 
in the liver (day 7) and lung (days 1, 3, 7 and 12). These microhistographs are representative of two mice per time point. Mag-
nification: ×20.
 Heart (Day 7) Kidney (Day 7) Brain (Day 7) Liver (Day 7)
Lung (Day 1) Lung (Day 3) Lung (Day 12) Lung (Day 7)
PCR amplification of an adenoviral genomic sequence after intranasal Ad inoculation Figure 5
PCR amplification of an adenoviral genomic sequence after intranasal Ad inoculation. After intranasal delivery of AdLuc, mice 
were sacrificed at day 3 and the total DNA was isolated from organs. PCR amplification of adenoviral genomic sequences and 
the GAPDH control was performed using the isolated DNA as the template and primers outlined in the Methods. The PCR 
reactions were then electrophoresed through a 1% agarose gel, stained with ethidium bromide, and visualized under UV light. 
The data is representative of 4 mice. OB = olfactory bulb, LN = lymph node.
   Trachea     Lung       OB       Brain      LN  Spleen
Ad sequence (720 bp)
GAPDH (550 bp)Genetic Vaccines and Therapy 2008, 6:5 http://www.gvt-journal.com/content/6/1/5
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rise at day 3 (Fig. 3E) which was comparable to that in the
trachea or olfactory bulb at the same time point (Table 1).
This supports the draining property of these lymph nodes
and suggests that these could be one of the primary
immune activation sites following i.n mucosal vaccina-
tion [19]. The virus may directly disseminate via lymph
and/or via infected antigen presenting cells to access the
draining lymph nodes. With respect to the latter, we have
recently observed in a separate study that fluorescently
labeled dendritic cells, upon intranasal delivery, could
subsequently be found in the cervical lymph nodes.
We have also assessed the level of inflammation in the
lung, liver, heart, kidney and brain at days 1, 3, 7 and 12
following i.n AdLuc delivery. As shown in Table 2 and Fig-
ure 4, following i.n Ad inoculation, tissue inflammatory
responses were seen primarily in the lung and to a much
lesser extent in the liver (with very mild inflammatory
infiltration in the perivascular area) while there was no
inflammation in the heart, kidney or brain. The lack of
inflammation in the heart and kidney may be due to the
lack of viral dissemination. The lack of inflammation in
the brain including olfactory bulb may be explained by
several considerations: 1) the virus gets into the olfactory
bulb via retrograde neurologic transfer but not through
the brain-blood barrier; 2) the virus is replication-defec-
tive and does not replicate within brain cells, which does
not cause the generation of sufficient chemotactic signals
for leukocyte recruitment; and 3) the brain-blood barrier
remains intact. Furthermore, lack of inflammation in the
olfactory bulb region could explain the sustained levels of
luciferase expression at this site, different from other tis-
sue sites (Table 1).
Distribution of adenovirus by PCR amplification after 
intranasal adenoviral vector delivery
As transgene expression may vary depending on the rela-
tive promoter activities between tissues, it may underesti-
mate the extent of adenoviral vector tissue dissemination.
To this end, we further assessed viral dissemination by
using PCR to detect adenoviral genomic sequences in var-
ious tissues following intranasal delivery. Mice were
infected with AdLuc and at 3 days following infection,
total DNA from various organs was analyzed using aden-
oviral genome-specific primers and PCR. Adenoviral gene
sequence was not seen in the trachea (Fig. 5), which sup-
ports the patchy GFP expression and relatively very low
luciferase activities. In comparison, a bright band was
seen for the lung and olfactory bulb, in agreement with
intense GFP and luciferase activities in these tissues (Fig.
5). Of note, the bright band observed for the spleen is in
contrast to the lack of GFP and luciferase activity in this
organ (Fig. 5). This observation suggests the dissemina-
tion of adenoviral vector to the spleen which is discordant
with transgene expression, in agreement with the study by
Johnson and colleagues, where intravenous administra-
tion of adenoviral vector resulted in a relatively high PCR
adenoviral genomic signal in the spleen, but a low luci-
ferase expression determined by optical imaging [20]. A
possible contributing factor may be that the CMV pro-
moter is less active in the resident immune cells in the
spleen compared with lung cells for example [20]. Of
importance, no adenoviral gene sequences were seen in
the brain, which correlates with a lack of both GFP and
luciferase activity, further supporting that the adenoviral
vector does not disseminate to the brain (Fig. 5).
In conclusion, our results indicate that intranasal mucosal
delivery of replication-defective recombinant adenoviral
vector results in gene transfer predominantly in the respi-
ratory system including the lung and transiently in the
draining cervical lymph nodes, while it does lead to a
moderate level of gene transfer in the olfactory bulb.
However, intranasal inoculation of adenoviral vector
leads to little or no viral dissemination to the major
region of the CNS, the brain. These experimental findings
support the efficaciousness of intranasal mucosal adeno-
viral-mediated vaccination. It is noteworthy that there
have been no reports of brain-inflammation-related side
effects after intranasal inoculation of Flumist – a live cold-
adapted influenza virus vaccine or adenoviral-vectored
vaccine in humans [1-3]. These observations together sup-
port the concept and feasibility of genetic-based intrana-
sal vaccination in humans.
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